Last updated on April 2017

Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients


Brief description of study

Chemotherapy induced diarrhea is seen in up to 40-80% of patients receiving this treatment for HER2 positive locally advanced or metastatic breast cancer. This diarrhea can significantly impact a patient's quality of life and ability to tolerate chemo/anti-HER2 therapy. This study will look at the efficacy of the drug crofelemer in preventing diarrhea in breast cancer patients.

Detailed Study Description

Various anti-diarrheal agents, such as loperamide, codeine, octreotide, are available for diarrhea management, but few are used in the prophylactic setting and none provide a targeted approach for treating chemotherapy induced diarrhea (CID). Pre-clinical studies have suggested that blocking EGFR results in excess chloride secretion and thus diarrhea. Crofelemer is an extract from the blood red bark of Croton lechleri that inhibits luminal chloride efflux by blocking the calcium activated chloride channel (CaCC) and cystic fibrosis transmembrane regulator (CFTR) chloride channels. Due to its size and polarity, it acts only luminally and is not systemically absorbed. It is currently FDA approved for use in preventing diarrhea in HIV/AIDS patients on anti-retroviral therapy.

Clinical Study Identifier: NCT02910219

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Paula R Pohlmann, MD, PhD

Lombardi Comprehensive Cancer Center
Washington, D.C., United States
  Connect »

Mahsa Mohebtash, MD

MedStar Union Memorial Hospital
Baltimore, MD United States
  Connect »

Yvonne Ottaviano, MD

Harry and Jeanette Weinberg Cancer Institute
Baltimore, MD United States
  Connect »